Today: January 17, 2019, 8:55 pm
  
Health

Novotech: Federal R&D Tax Support Keeps Australia Competitive

Novotech: Federal R&D Tax Support Keeps Australia Competitive
PR-Inside.com: 2018-05-18 17:20:58
SYDNEY, AUS, May 18, 2018 - (ACN Newswire) - Leading Asia Pacific CRO Novotech commended the Turnbull Government's Federal Budget decision to exclude clinical trials activity from a A$4m cap on cash refunds, or any lifetime cap on refunds.


Novotech CEO Dr John Moller said the move reaffirms Australian's lead position in attracting foreign investment for drug development and sends a message to the international biopharma community that Australia is the place to conduct research.


"The clinical trial sector not only delivers around A$1billion to the Australian economy annually, it also supports the Australian biopharma industry growth and expertise for the development of new life-changing therapies for both the Australian and world markets.


Novotech is an Asia-Pacific specialist contract research organization (CRO) established in 1996, headquartered in Australia with offices in eleven countries throughout the region.


See the latest data on Australian and also Asia clinical trials here: www.novotech-cro.com/resources.


"More than A$650 million in clinical trial investment each year comes from overseas biopharma companies wanting fast yet high-quality research. According to our clients, the R&D Tax Incentive is a significant factor in their decision to invest in Australian research," said Dr Moller.


He said the Government announced in the budget that it is excluding R&D tax offsets for clinical trials from the $4 million cap on cash refunds, "recognising the critical role of R&D expenditure on clinical trials in developing life changing drugs and devices."


According to the Budget announcement the Government will also:


" ... introduce a new research and development premium for companies with aggregated annual turnover of $20 million or more, which provides higher rates of R&D support for higher R&D intensity (that is, the proportion of R&D expenditure over total annual expenditure).


The research and development premium will provide multiple rates of non-refundable R&D tax offsets, increasing with the intensity of the claimant's incremental R&D expenditure.


The ... reforms will support and reward higher, more intensive, additional R&D investment."


About Novotech - www.novotech-cro.com


Headquartered in Sydney, Novotech is internationally recognised as the leading regional full-service contract research organisation (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.


Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management.


Novotech's strong Asia Pacific presence includes running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners.


For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us-0.


Media Contact


team@dmgpr.com


Susan Fitzpatrick-Napier


AU +61 2 8218 2144


USA +1 650 798 5238


Topic: Press release summary


Sectors: HealthCare


www.acnnewswire.com


From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network

Press Information


Published by
ACN Newswire
+65 6304 8926
e-mail
www.acnnewswire.com



# 504 Words
Related Articles
More From The Author
Hari Raya Light Up 2018 in Singapore [..]
With Light Displays Bearing Malay Cultural Icons SINGAPORE, May 17, 2018 - (ACN Newswire) - Hari Raya Light Up 2018 [..]
Stripe and JCB Sign MOU for Global [..]
Enabling JCB brand payment at merchants around the world using the Stripe payment platform San Francisco and Tokyo, May 17, [..]
TEPCO and Pocket Queries to Collaborate on [..]
TOKYO, May 17, 2018 - (JCN Newswire) - Electric industry leader Tokyo Electric Power Company Holdings Inc. (TEPCO) announced today [..]
Loyyal Corporation Expands Global Reach to Australia [..]
REFFIND (ASX: RFN) appointed Value Added Reseller and exclusive Network Operator in territory SAN FRANCISCO, May 14, 2018 - [..]
Global Exclusive Premier of CCCX on Coinsuper [..]
HONG KONG, May 14, 2018 - (ACN Newswire) - Coinsuper, a leading crypto exchange in Hong Kong, is announcing that [..]
 
More From Health
Best Hospitals in India empanel with Forerunners [..]
17 Jan 2019, Delhi Numerous Medical Tourists easily accessing Best Hospitals in India empanel with Forerunners Healthcare Consultants [..]
Gamma Knife Surgery in India offer high [..]
India offers high Quality and affordable treatment at affordable cost including the Low-cost Gamma knife surgery India. There [..]
Spine and Neuro Surgery Hospital India planning [..]
16-01-2019, Chennai: The requirement of appropriate Spine and Neuro Surgery treatment is very high all over the globe. Spine and [..]
Medical Tourists Flocking To India for Low [..]
10 DEC 2018: Also known as Renal Cancer, Kidney Cancer is a very prevalent form of Cancer and there are [..]
Diabetes Therapy Program Target Market Is Growing [..]
The Study record offers a total analysis of the marketplace as well as has a future pattern, present development elements, [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.